Abstract:Introduction: Targeted biologic immunomodulatory therapies have had a major impact in rheumatoid arthritis (RA) treatment, including tumor necrosis factor (TNF)-α inhibition, B-cell depletion, interference in T-cell costimulation and interleukin (IL)-1 and IL-6 inhibition. Along with the recognition of the importance of early, aggressive disease-modifying antirheumatic drugs (DMARDs) grounded in the use of methotrexate, the introduction of biologic DMARDs (bDMARDs) has provided significantly improved outcomes in patients with RA with a goal of true remission, or at least a state of very low disease activity, now possible in many. There are a number of methods to inhibit cytokines, cellular receptors and pathways of signal transduction that have been used thus far and are in development. In some cases, the method of target inhibition and differences in molecular construct has impacted efficacy and/or safety; whereas, in other cases, similar safety and/or efficacy signals across compounds have demonstrated class- or target-related effects. As the development of targeted therapies moves forward, it is increasingly important to understand the role of the target both in RA disease pathogenesis and normal host defense and the mechanisms of target inhibition. Areas covered: This review covers the targets of therapy for biologic agents in rheumatic diseases, their molecular constructs and implications on efficacy and safety, with focus on approved treatments for RA. Expert opinion: Advances in molecular biology have provided a number of different ways to impact pathobiologically relevant pathways and targets in terms of the molecular construct of individual compounds. The use of these agents have provided important mechanistic insights into disease pathogenesis, and in some cases are associated with differences in efficacy and safety among agents even with the same downstream target. As bDMARDs identify promising mechanisms, oral agents that target or specifically regulate downstream pathways are made possible.

Therapeutic Potential of TNFα Inhibitors in Chronic Inflammatory Disorders: Past and Future

Targeting Fusion Proteins of the Interleukin Family: A Promising New Strategy for the Treatment of Autoinflammatory Diseases.

Past, Present and (Foreseeable) Future of Biological Anti-TNF Alpha Therapy

Selective Targeting of TNF Receptors as a Novel Therapeutic Approach

Research progress on tumor necrosis factor inhibitors

Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer

[Biologics for Targeting Inflammatory Cytokines and Their Clinical Application].

Successful Treatment of Animal Models of Acute Graft-Versus-Host Disease with Small-Molecule TNF Inhibitor

Discovery of Cyclic Peptide Inhibitors Targeted on TNFα-TNFR1 from Computational Design and Bioactivity Verification

The Role of Tumor Necrosis Factor Alpha (TNF-α) in Autoimmune Disease and Current TNF-α Inhibitors in Therapeutics

Novel Agents in the Future: Therapy Beyond Anti-Tnf Agents in Inflammatory Bowel Disease.

Progress of Tumor Necrosis Factor Alpha Inhibitors in Treatment of Rheumatoid Arthritis

The Therapeutic Landscape of Rheumatoid Arthritis: Current State and Future Directions

Promising Therapeutic Targets for Treatment of Rheumatoid Arthritis

Biologics targeted at TNF: design, production and challenges.

Research advance of selective inhibitor of tumornecrosis factor receptor

Targeting TNF/TNFR superfamilies in immune-mediated inflammatory diseases

Target effector role of vascular endothelium in the inflammatory response: insights from the clinical trial of anti-TNF alpha antibody in rheumatoid arthritis.

Targeting Tumor Necrosis Factor Receptor 1 with Selected Aptamers for Anti-Inflammatory Activity

Efficacy and safety implications of molecular constructs of biological agents for rheumatoid arthritis

Neurological Side Effects of TNF-α Inhibitors Revisited: A Review of Case Reports